Markets
PTN

Dicerna Pharmaceuticals (DRNA) Rises: Stock Climbs 14%

Dicerna Pharmaceuticals, Inc.DRNA was a big mover last session, as the company saw its shares rise over 14% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.45 to $2.91 in the past one-month time frame.

The company has seen one negative estimate revision in the last 30 days; while the Zacks Consensus Estimate remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Dicerna sports a Zacks Rank #1 (Strong Buy) while its Earnings ESP is positive.

Dicerna Pharmaceuticals, Inc. Price

Dicerna Pharmaceuticals, Inc. Price | Dicerna Pharmaceuticals, Inc. Quote

Another similarly-ranked stock in the same industry is Palatin Technologies, Inc. PTN . You can see the complete list of today's Zacks #1 Rank stocks here .

Is DRNA going up? Or down? Predict to see what others think: Up or Down

Just Released - Driverless Cars: Your Roadmap to Mega-Profits Today

In this latest Special Report, Zacks' Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making - autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Palatin Technologies, Inc. (PTN): Free Stock Analysis Report

Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PTN DRNA

Other Topics

Investing Stocks

Latest Markets Videos